Premium
Phase II randomized clinical trial of LC9018 concurrently used with radiation in the treatment of carcinoma of the uterine cervix. Its effect on tumor reduction and histology
Author(s) -
Okawa Tomohiko,
Kita Midori,
Arai Tatsuo,
Iida Kouyo,
Dokiya Takushi,
Takegawa Yoshihiro,
Hirokawa Yutaka,
Yamazaki Kazuto,
Hashimoto Shozo
Publication year - 1989
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19891101)64:9<1769::aid-cncr2820640902>3.0.co;2-g
Subject(s) - medicine , radiation therapy , randomized controlled trial , leukopenia , adjuvant , cervix , carcinoma , therapeutic effect , oncology , cancer , gastroenterology , chemotherapy
The clinical efficacy of LC9018, a biological response modifier prepared from heat‐killed Lactobacillus casei YIT9018, used in combination with radiation was studied in a randomized controlled trial on 61 patients with carcinoma of the uterine cervix of Stage IIB or III. The combination therapy with LC9018 demonstrated a significant effect on tumor reduction, compared with radiation therapy alone, at the cumulative doses of 15‐Gy and 30‐Gy external irradiation ( P < 0.05). Histologic study confirmed that LC9018 also enhanced the therapeutic effect of the irradiation. Moreover, LC9018 seemed to be useful in protecting the patients from leukopenia during radiotherapy. This study suggests that LC9018, when used in combination with radiotherapy, will be an effective adjuvant immunotherapeutic agent. More studies in a large series of patients will, however, be needed to establish its long‐term efficacy, safety, and effects on both prognosis and enhancing radiotherapy.